All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What are the key updates to the NCCN guidelines® for CLL/SLL?

Apr 28, 2023

Following recent changes to the NCCN guidelines®, the Lymphoma Hub was pleased to speak to Deborah Stephens, Huntsman Cancer Institute, Utah, US. We asked, What are the key updates to the NCCN guidelines® for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia?

What are the key updates to the NCCN guidelines® for CLL/SLL?

Stephens explains that the Bruton’s tyrosine kinase inhibitor, ibrutinib, has been moved from the ‘preferred regimens’ category to the ‘other recommended regimens’ category for patients with CLL. This was based on findings from the phase III ALPINE (NCT03734016) and ELEVATE-RR (NCT02477696) clinical trials, which demonstrated equal or better efficacy and reduced toxicity for zanubrutinib and acalabrutinib, respectively, compared with ibrutinib for relapsed/refractory CLL.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

What kind of 1L DLBCL patients should now be treated with Pola-R-CHP (choose all options that apply)?
4 votes - 1 day left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox